328 related articles for article (PubMed ID: 33091440)
21. Analysis of gamma-glutamyltransferase in acute promyelocytic leukemia patients undergoing arsenic trioxide treatment.
Sui M; Wei H; Zhang Q; Xiu R; Shen X; Zhang Z; Zhou J
Hematology; 2021 Dec; 26(1):58-64. PubMed ID: 33402059
[TBL] [Abstract][Full Text] [Related]
22. Successful Treatment of Acute Promyelocytic Leukemia Complicated with Endometrial Cancer by Arsenic Trioxide.
Sugiura H; Nishimori H; Matsuoka H; Nakamura K; Fujii K; Fujii N; Matsuoka KI; Maeda Y
Acta Med Okayama; 2021 Apr; 75(2):219-224. PubMed ID: 33953429
[TBL] [Abstract][Full Text] [Related]
23. Autophagy: New Insights into Mechanisms of Action and Resistance of Treatment in Acute Promyelocytic leukemia.
Moosavi MA; Djavaheri-Mergny M
Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31330838
[TBL] [Abstract][Full Text] [Related]
24. Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: an useful salvage therapy.
Huan SY; Yang CH; Chen YC
Leuk Lymphoma; 2000 Jul; 38(3-4):283-93. PubMed ID: 10830735
[TBL] [Abstract][Full Text] [Related]
25. Arsenic trioxide induces accumulation of cytotoxic levels of ceramide in acute promyelocytic leukemia and adult T-cell leukemia/lymphoma cells through de novo ceramide synthesis and inhibition of glucosylceramide synthase activity.
Dbaibo GS; Kfoury Y; Darwiche N; Panjarian S; Kozhaya L; Nasr R; Abdallah M; Hermine O; El-Sabban M; de Thé H; Bazarbachi A
Haematologica; 2007 Jun; 92(6):753-62. PubMed ID: 17550847
[TBL] [Abstract][Full Text] [Related]
26. Relapsed APL patient with variant NPM-RARalpha fusion responded to arsenic trioxide-based therapy and achieved long-term survival.
Chen Y; Gu L; Zhou C; Wu X; Gao J; Li Q; Zhu Y; Jia C; Ma Z
Int J Hematol; 2010 May; 91(4):708-10. PubMed ID: 20405253
[TBL] [Abstract][Full Text] [Related]
27. Interaction between arsenic trioxide and human primary cells: emphasis on human cells of myeloid origin.
Binet F; Antoine F; Girard D
Inflamm Allergy Drug Targets; 2009 Mar; 8(1):21-7. PubMed ID: 19275690
[TBL] [Abstract][Full Text] [Related]
28. Survivin isoform expression in arsenic trioxide-treated acute promyelocytic leukemia cell line and patients: The odd expression pattern of survivin-2α.
Zaki Dizaji M; Ghaffari SH; Hosseini E; Alizadeh N; Rostami S; Momeny M; Alimoghaddam K; Ghavamzadeh A
Asia Pac J Clin Oncol; 2017 Apr; 13(2):e21-e30. PubMed ID: 27770503
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of adverse cardiac effects induced by arsenic trioxide, a potent anti-APL drug.
Raghu KG; Yadav GK; Singh R; Prathapan A; Sharma S; Bhadauria S
J Environ Pathol Toxicol Oncol; 2009; 28(3):241-52. PubMed ID: 19888912
[TBL] [Abstract][Full Text] [Related]
30. Gelling Bodies: Understanding the Mechanisms Underlying Arsenic Trioxide Action.
Salomoni P
Cancer Discov; 2023 Dec; 13(12):2505-2506. PubMed ID: 38084094
[TBL] [Abstract][Full Text] [Related]
31. Molecular mechanisms of the antileukemia activities of retinoid and arsenic.
Nitto T; Sawaki K
J Pharmacol Sci; 2014; 126(3):179-85. PubMed ID: 25319615
[TBL] [Abstract][Full Text] [Related]
32. Molecular targets of arsenic trioxide in malignant cells.
Miller WH
Oncologist; 2002; 7 Suppl 1():14-9. PubMed ID: 11961205
[TBL] [Abstract][Full Text] [Related]
33. A novel differentiation-inducing therapy for acute promyelocytic leukemia with a combination of arsenic trioxide and GM-CSF.
Muto A; Kizaki M; Kawamura C; Matsushita H; Fukuchi Y; Umezawa A; Yamada T; Hata J; Hozumi N; Yamato K; Ito M; Ueyama Y; Ikeda Y
Leukemia; 2001 Aug; 15(8):1176-84. PubMed ID: 11480559
[TBL] [Abstract][Full Text] [Related]
34. Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia.
Lengfelder E; Hofmann WK; Nowak D
Leukemia; 2012 Mar; 26(3):433-42. PubMed ID: 21904379
[TBL] [Abstract][Full Text] [Related]
35. Activation of PPARγ intensified the effects of arsenic trioxide in acute promyelocytic leukemia through the suppression of PI3K/Akt pathway: Proposing a novel anticancer effect for pioglitazone.
Esmaeili S; Safaroghli-Azar A; Pourbagheri-Sigaroodi A; Salari S; Gharehbaghian A; Hamidpour M; Bashash D
Int J Biochem Cell Biol; 2020 May; 122():105739. PubMed ID: 32169580
[TBL] [Abstract][Full Text] [Related]
36. Multicenter randomized trial of arsenic trioxide and Realgar-Indigo naturalis formula in pediatric patients with acute promyelocytic leukemia: Interim results of the SCCLG-APL clinical study.
Yang MH; Wan WQ; Luo JS; Zheng MC; Huang K; Yang LH; Mai HR; Li J; Chen HQ; Sun XF; Liu RY; Chen GH; Feng X; Ke ZY; Li B; Tang YL; Huang LB; Luo XQ
Am J Hematol; 2018 Dec; 93(12):1467-1473. PubMed ID: 30160789
[TBL] [Abstract][Full Text] [Related]
37. miR-603 promotes cell proliferation and differentiation by targeting TrkB in acute promyelocytic leukemia.
Li H; Hou J; Fu Y; Zhao Y; Liu J; Guo D; Lei R; Wu Y; Tang L; Fan S
Ann Hematol; 2023 Dec; 102(12):3357-3367. PubMed ID: 37726492
[TBL] [Abstract][Full Text] [Related]
38. The pharmacokinetics of therapeutic arsenic trioxide in acute promyelocytic leukemia patients.
Ghiuzeli CM; Stýblo M; Saunders J; Calabro A; Budman D; Allen S; Devoe C; Dhingra R
Leuk Lymphoma; 2022 Mar; 63(3):653-663. PubMed ID: 34689693
[TBL] [Abstract][Full Text] [Related]
39. Arsenic trioxide as first-line treatment for acute promyelocytic leukemia.
Leu L; Mohassel L
Am J Health Syst Pharm; 2009 Nov; 66(21):1913-8. PubMed ID: 19850784
[TBL] [Abstract][Full Text] [Related]
40. Understanding the molecular pathogenesis of acute promyelocytic leukemia.
Lo-Coco F; Hasan SK
Best Pract Res Clin Haematol; 2014 Mar; 27(1):3-9. PubMed ID: 24907012
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
